Johns Hopkins ABX Guide
Boceprevir
INDICATIONS
FDA
FDA
- Boceprevir is indicated for the treatment of HCV (genotype1, used in combination with peg-INF + ribavirin) in adult patients with compensated liver disease, including cirrhosis.
- Boceprevir may be used in either treatment-naïve patients or those who have failed previously interferon/ribavirin therapy.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 4, 2018
Citation
Smith, Janessa, and Paul A Pham. "Boceprevir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540605/5/Boceprevir.
Smith J, Pham PA. Boceprevir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540605/5/Boceprevir. Accessed May 3, 2025.
Smith, J., & Pham, P. A. (2018). Boceprevir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540605/5/Boceprevir
Smith J, Pham PA. Boceprevir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2025 May 03]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540605/5/Boceprevir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Boceprevir
ID - 540605
A1 - Smith,Janessa,Pharm.D. BCPS
AU - Pham,Paul,PharmD
Y1 - 2018/03/04/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540605/5/Boceprevir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
